Tadashi Namisaki
Overview
Explore the profile of Tadashi Namisaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
1966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsuji Y, Namisaki T, Takaya H, Nishimura N, Noguchi R, Asada S, et al.
Dig Dis Sci
. 2025 Mar;
PMID: 40072765
Aim: The incidence of intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC) still remains high after radiofrequency ablation (RFA). However, serum alpha-fetoprotein (AFP) has insufficient screening power. This study aimed...
2.
Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, et al.
J Gastroenterol
. 2025 Mar;
PMID: 40053108
Background: Covert hepatic encephalopathy (CHE) leads to devastating outcomes in patients with cirrhosis. This study aims to elucidate the current management and future perspectives of CHE in Japan. Methods: A...
3.
Kawaratani H, Namisaki T, Kondo Y, Tatsumi R, Kawabe N, Tanabe N, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004887
Rifaximin is a therapeutic agent for patients with hepatic encephalopathy (HE); however, there is little data on the effects of its long-term (>1 year) administration in Japanese patients with cirrhosis....
4.
Kaji K, Takeda S, Iwai S, Nishimura N, Sato S, Namisaki T, et al.
Antioxidants (Basel)
. 2024 Nov;
13(11).
PMID: 39594556
Imeglimin promotes glucose-stimulated insulin secretion in the pancreas in a glucose-dependent manner and inhibits gluconeogenesis in the liver. Meanwhile, imeglimin can improve mitochondrial function in hepatocytes. We used a nondiabetic...
5.
Matsuda T, Kaji K, Nishimura N, Asada S, Koizumi A, Tanaka M, et al.
Heliyon
. 2024 Oct;
10(19):e38647.
PMID: 39398008
Cabozantinib, a multiple tyrosine kinase inhibitor targeting AXL, vascular endothelial growth factor receptor (VEGFR), and MET, is used clinically to treat certain cancers, including hepatocellular carcinoma. This study aimed to...
6.
Koizumi A, Kaji K, Nishimura N, Asada S, Matsuda T, Tanaka M, et al.
World J Gastroenterol
. 2024 Aug;
30(28):3428-3446.
PMID: 39091710
Background: Alcohol-associated liver disease (ALD) is a leading cause of liver-related morbidity and mortality, but there are no therapeutic targets and modalities to prevent ALD-related liver fibrosis. Peroxisome proliferator activated...
7.
Tomooka F, Kitagawa K, Mitoro A, Fujinaga Y, Nishimura N, Namisaki T, et al.
DEN Open
. 2024 Jul;
5(1):e404.
PMID: 39011511
Objectives: To evaluate the results of inside stent therapy for unresectable malignant hilar biliary obstruction and identify factors related to stent patency duration. Methods: Of 44 patients who underwent initial...
8.
Iwai S, Akahane T, Takaya H, Kubo T, Tomooka F, Shibamoto A, et al.
Hepatol Res
. 2024 Jun;
54(12):1116-1127.
PMID: 38838066
Aim: Esophagogastric varices (EGV) are a serious complication of hepatitis C virus (HCV)-related liver cirrhosis (HCV-LC). In most cases, portal hypertension improves after a sustained virologic response (SVR) is achieved...
9.
Hara N, Hiraoka A, Nakai M, Shiraki M, Namisaki T, Miyaaki H, et al.
Hepatol Res
. 2024 May;
54(11):1099-1105.
PMID: 38801372
Aim: It is not uncommon to encounter outpatients in the hepatology department with harmful alcohol habits. When treating such chronic liver disease (CLD) patients, an adequate intervention method for harm...
10.
Tachiiri T, Minamiguchi K, Taiji R, Sato T, Toyoda S, Matsumoto T, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730577
Aim: Transarterial chemoembolization (TACE) combined with lenvatinib, employing a 4-day lenvatinib administration followed by TACE without an interval (short-term LEN-TACE), was performed for hepatocellular carcinoma (HCC). The aim was to...